Quality of life ‐ not reported · patients undergoing non‐cardiac surgery/invasive procedures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality up to 30 days ‐ not reported · patients undergoing non‐cardiac surgery/invasive procedures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Bleeding ‐ major/excessive · patients undergoing non‐cardiac surgery/invasive procedures
It is very uncertain whether prophylactic plasma transfusion before surgery/invasive procedures changes major bleeding within 24 hours № of participants: 21 (1 RCT) compared with alternative haemostatic agents (very low certainty).
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
APX vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation
1 finding from 1 review
Intervention not reported
RVX (high dose, 10 mg to 20 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation
1 finding from 1 review
Intervention not reported
RVX (low dose, 2.5 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation
1 finding from 1 review
Intervention not reported
DAB (low dose, 110 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation
1 finding from 1 review
Intervention not reported
DAB (high dose, 150 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation
1 finding from 1 review
Intervention not reported
APX vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation
1 finding from 1 review
Intervention not reported
RVX (high dose, 10 mg to 20 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation
1 finding from 1 review
Intervention not reported
RVX (low dose, 2.5 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation
1 finding from 1 review
Intervention not reported
DAB (low dose, 110 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation
1 finding from 1 review
Intervention not reported
DAB (high dose, 150 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation
1 finding from 1 review
Intervention not reported
APX vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation
1 finding from 1 review
Intervention not reported
RVX (high dose, 10 mg to 20 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation
1 finding from 1 review
Intervention not reported
RVX (high dose, 10 mg to 20 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation
1 finding from 1 review
Intervention not reported
RVX (low dose, 2.5 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation
1 finding from 1 review
Intervention not reported
DAB (low dose, 110 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation
1 finding from 1 review
Intervention not reported
DAB (high dose, 150 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation
1 finding from 1 review
Intervention not reported
APX vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation
1 finding from 1 review